ABBOTT INDIA LIMITED

Biotechnology Reagents Market to grow at 7.98% CAGR, reaching USD 173.87 Bn by 2030. North America leads growth. Key players include Life Technologies, Bio-Rad, Thermo Fisher Scientific, and others. Market driven by R&D investments in agriculture, pharmaceuticals, and food industries.

Lisa Earnhardt, Abbott Medical Devices President, emphasizes innovation as core to Abbott's mission, focusing on device design, customer needs, and diversity in medtech. Abbott aims to treat 3 billion people by 2030, with 2023 medical device sales growing 14% to $16.9 billion, moving the company from No. 10 to No. 8 in the Medtech Big 100 ranking. Earnhardt highlights the importance of understanding customer needs and leveraging technology to solve healthcare challenges, exemplified by Abbott's innovations in cardiac rhythm management, diabetes care, and neuromodulation. She also advocates for increasing diversity in medtech to expand healthcare access, encouraging women in the industry to trust their abilities and continuously learn.

DelveInsight's 'Adrenoleukodystrophy Pipeline Insight, 2024' report details 11+ treatment therapies by 10+ companies, including Autobahn Therapeutics, Viking Therapeutics, and SwanBio Therapeutics. Emerging therapies like ABX-002, VK0214, and SBT101 are expected to impact the market. Minoryx Therapeutics plans to re-examine Nezglyal's approval after CHMP's refusal.

Senseonics and Ascensia Diabetes Care received FDA clearance for Eversense 365, the first implantable glucose sensor wearable for a year, doubling the current sensor's wear time. The CGM, implantable under the skin with a removable transmitter, is for adults with Type 1 or Type 2 diabetes and has an integrated CGM designation for automated insulin delivery systems. Senseonics CEO Tim Goodnow anticipates this as a significant catalyst for the company. The sensor requires less frequent calibration and is expected to launch in the fourth quarter, aiming to double sales and user base in 2025.

QuidelOrtho secures FDA clearance for Vitros Syphilis Assay, aiming to address the syphilis epidemic in the U.S. under new CEO Brian Blaser. The company plans to enhance production, invest in new tech, and expand markets, with a focus on adding new tests like syphilis to its portfolio.

Abbott's TRANSCEND study evaluates a deep brain stimulation (DBS) device for difficult-to-treat depression, enrolling 100 participants who've failed at least four previous treatments. The trial is double-blind, randomized, and sham-controlled, aiming to assess DBS's efficacy by comparing Montgomery-Asberg Depression Rating Scale (MADRS) scores between treatment and control groups.

FDA approves Biotronik's stylet-driven lead and delivery catheter system for left bundle branch area pacing, based on BIO-CONDUCT trial results showing high implant success and low complications.

The Molecular Diagnostics and NAT Market is projected to grow from USD xx.x Billion in 2023 to USD xx.x Billion by 2031, driven by technological advancements, increasing disease prevalence, and demand for personalized medicine. Key manufacturers include Roche, Abbott, BD, Biomerieux, Qiagen, Thermo Fisher Scientific, Agilent, GenMark, Siemens Healthcare, and AutoGenomics. Challenges include regulatory hurdles, high costs, and data interpretation complexities.

The IoT Medical Devices market is projected to reach USD 503.6 billion by 2032 from USD 41.4 billion in 2023, growing at a CAGR of 32.0%. This growth is driven by technological advancements, rising healthcare demands, and the adoption of connected devices for real-time health monitoring. Key segments include medical devices, systems and software, and services, with cellular technology leading in adoption. North America dominates the market, while Asia-Pacific shows rapid growth. Major companies include Apple, Intel, and Medtronic.

Daye's diagnostic tampon, designed for self-collection of vaginal and cervical fluids to detect STIs and HPV, outperformed conventional swabs in a trial with 250 participants. The tampon, approved in the UK and US, is expected to increase STI and HPV screening participation. The trial's success relied on efficient patient recruitment strategies, including digital marketing and pre-consenting.